In the Harvesting Session the World Café moderators will summarize the results of their discussions and highlight key findings.
Head of Operations Healthcare Life Science Limited, Healthcare Pharmaceuticals Limited
Under the umbrella of PHARMA 4.0, Initiating brand new country largest pharmaceutical project in 40 acres of land with the value of 400 millions USD investment scope of different portfolio and dosage forms targeting local and US FDA Market ensuring data integrity, productivity and green factory by design.
Vice President, Head Quality Operations API, Cipla
Sarang Bhunje is Vice President, Head Quality Operations API with Cipla for 1+ years. Through is expierences as Associate Vice President for 7+ years with Sun Pharma and as Associate Director, Quality Assurance with Reddy's Laboratories he brings great knowledge to his current position.
Senior Manager - Global Regulatory Affairs (CMC/Strategy), Pfizer, Inc.
Brix Bayuga is Senior Manager Global Regulatory Affairs (CMC/Strategy) at Pfizer, where he has worked for more than 12 years. He has more than 16 years of professional experience in dealing with Health Authorities globally, expertise in authoring dossier submissions (new submissions, lifecycle management, BOH responses), developing and executing regulatory strategies, and compliance, as well as a hands-on operational experience working with manufacturing sites.
Head of Operational Technologies APAC, IT Director, Lonza Group
Stephane Delatorre has 30 years experience in IT and OT for Pharmaceutical and Chemical industry. He graduated from French University with a Masters Degree in computer science. He has 15 years experience in headquarters of Chemical/Pharmaceutical companies in Basel-Switzerland, in diverse leading positions with increased responsibilities covering successively IT Infrastructure, Supply Chain Systems, IT Project management and IT Project Management/Portfolio Management methodologies. Delatorre moved to Singapore in 2005 for leading the implementation of IT Systems for the a new greenfield Pharmaceutical tableting plant project, and subsequently took responsibility of the design of IT Infrastructure and Systems for a new large Pharma Biotech manufacturing facility. He transferred to Lonza Singapore in 2009 to lead the implementation of all IT Infrastructure and Systems required to run a new large scale multi product Pharma Biological Custom Manufacturing facility.He took subsequently the lead of IT for Lonza Singapore, India and Japan.Then he moved for 2 years to a global role in IT Innovation.Since 2019,he is in the role of Head of APAC Operational Technology for LONZA.
Healthcare Pharmaceuticals Limited
Healthcare Pharmaceuticals Ltd. is one of the leading pharmaceutical company in Bangladesh having certified by the international pharmaceutical regulatory authorities like TGA (Australia), NPRA (Malaysia), MCAZ (Zimbabwe), TFDA (Tanzania) etc. HPL is focused on innovation and provides healthcare solutions that improves and extends people’s lives. From prevention to treatment, HPL transforms scientific innovation into healthcare solutions in Antihistamine, Antiemetic, Anti-diabetic, Analgesic or Antipyretic, Anti-infective, Bone Care, Biotech and Oncology, CNS Drug, Cardiovascular, Dermatological Products, Respiratory Care, Ophthalmic, Vitamin & Mineral and many other areas. Healthcare started its journey in 1988 by establishing a company named Healthcare Distribution Limited in association with Roche Limited, a Switzerland based renowned multinational company. Until 2001 HPL was responsible for importing and distributing Roche products to the local market. In 1996 HPL decided to establish its own pharmaceutical plant to produce the products those are imported from Roche, Switzerland and other local generics for indigenous market. Now Healthcare is the fastest growing organization in the pharmaceutical industry of Bangladesh. We are now producing more than two hundred products with various types of dosage forms which includes Tablets, Capsules, Liquids, Dry syrups, Creams & Ointments, Gels, Small Volume Parenteral, and Eye Drops covering almost all therapeutic classes. There are also numerous products in the launching pipeline for local and overseas markets in Asia, Africa and CIS region.
Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.
For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of Caring for Life and deep-rooted community links wherever it is present, make it a partner of choice for global health bodies and stakeholders.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma & Biotech segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases. Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live. Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.